BACKGROUND/AIM: To describe the role of baseline gallium (Ga)-68 DOTATATE positron emission tomography (PET)/computed tomography (CT) in the prediction of the response to peptide receptor radionuclide therapy (PRRT) using lutetium (Lu)-177 DOTATATE. MATERIALS AND METHODS: Analysis was made of baseline Ga-68 DOTATATE PET/CT images of 29 patients (17 females and 12 males; mean age: 50.7 ± 14.6 years) with metastatic neuroendocrine tumors who received PRRT with Lu-177 DOTATATE. Maximum standardized uptake values (SUVmax) of reference lesions and their ratios to physiological uptake organs were calculated. The relationship between these values and the radiological response was analyzed. RESULTS: Partial response was observed in 8 (28%) patients, stable disease in 18 (62%) patients, and progressive disease in 3 (10%) patients. Mean SUVmax of reference lesions was calculated as 23.8 ± 20.5 (min-max: 5.1-87.3). There was no significant correlation between radiological responses and SUVmax of reference lesions and their ratios to other organs. CONCLUSION: Baseline Ga-68 DOTATATE PET/CT helps to show somatostatin receptor expression status and disease stage in patients who are candidates for PRRT. However, SUVs do not have a role in the prediction of treatment response.
BACKGROUND/AIM: To describe the role of baseline gallium (Ga)-68 DOTATATE positron emission tomography (PET)/computed tomography (CT) in the prediction of the response to peptide receptor radionuclide therapy (PRRT) using lutetium (Lu)-177 DOTATATE. MATERIALS AND METHODS: Analysis was made of baseline Ga-68 DOTATATE PET/CT images of 29 patients (17 females and 12 males; mean age: 50.7 ± 14.6 years) with metastatic neuroendocrine tumors who received PRRT with Lu-177 DOTATATE. Maximum standardized uptake values (SUVmax) of reference lesions and their ratios to physiological uptake organs were calculated. The relationship between these values and the radiological response was analyzed. RESULTS: Partial response was observed in 8 (28%) patients, stable disease in 18 (62%) patients, and progressive disease in 3 (10%) patients. Mean SUVmax of reference lesions was calculated as 23.8 ± 20.5 (min-max: 5.1-87.3). There was no significant correlation between radiological responses and SUVmax of reference lesions and their ratios to other organs. CONCLUSION: Baseline Ga-68 DOTATATE PET/CT helps to show somatostatin receptor expression status and disease stage in patients who are candidates for PRRT. However, SUVs do not have a role in the prediction of treatment response.
Authors: Sander C Ebbers; Muriël Heimgartner; Maarten W Barentsz; Rachel S van Leeuwaarde; Mark J C van Treijen; Marnix M E G Lam; Arthur J A T Braat Journal: Eur J Hybrid Imaging Date: 2021-12-09
Authors: Marta Opalińska; Karolina Morawiec-Sławek; Adrian Kania-Kuc; Ibraheem Al Maraih; Anna Sowa-Staszczak; Alicja Hubalewska-Dydejczyk Journal: Front Endocrinol (Lausanne) Date: 2022-08-15 Impact factor: 6.055
Authors: Maria Isabel Del Olmo-Garcia; Stefan Prado-Wohlwend; Alexia Andres; Jose M Soriano; Pilar Bello; Juan Francisco Merino-Torres Journal: Biomedicines Date: 2021-12-01
Authors: M Albertelli; A Dotto; C Di Dato; P Malandrino; R Modica; A Versari; A Colao; D Ferone; A Faggiano Journal: Rev Endocr Metab Disord Date: 2021-09 Impact factor: 9.306